Regarding Comments by Yolcu et al. on “Evaluation of Choroidal Thickness in Ankylosing Spondylitis Using Optical Coherence Tomography”

Kola, Mehmet; Kalkişim, Ahmet; Karkucak, Murat; Türk, Adem; Çapkın, Erhan; Can, Ipek; Serdar, Omer Faruk; Mollamehmetoğlu, Süleyman; Ayar, Ahmet

doi:10.3109/09273948.2014.999379

Cited by 1 publication

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent OCT study, we determined greater ChT in patients with AS even without uveitis attacks compared to the healthy population. [ 5 ] This finding, identified for the first time in the literature, tempts to presume that ChT could be an early indicator of ocular involvement in AS, particularly when there are no evident uveitis attacks.…”

Section: Discussionmentioning

confidence: 92%

“…The prior power of the study was set as 80% and 5% significance level. And, in the light of the findings obtained from our previous study on ChT in patients with AS,[ 5 ] 25 patients were needed. Post-hoc power analysis (using the original data from our study population of 31 patients) yielded 78.2% power (the normal approximation method) using the OpenEpi version 3.01.…”

Section: Methodsmentioning

confidence: 99%

“…In a previous study, we determined high choroidal thickness (ChT) in patients with AS. [ 5 ] Considering the dense vascular structure and susceptibility of the choroid to inflammatory processes, ChT measurement can be used to monitor the status of systemic inflammation, particularly when ocular involvement is present.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Infliximab Therapy Provides Beneficial Effects for Choroidal Thickness Increase in Patients With Active Ankylosing Spondylitis: A Possible Mechanism Mediating the Suppressing of Uveitis Attacks

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objectives This study aims to quantitatively assess the profile of the choroidal thickness (ChT) in patients with ankylosing spondylitis (AS) using optical coherence tomography (OCT), and to examine whether the posterior eye segment abnormalities in active AS patients are reversible by infliximab therapy. Patients and methods October 2014 and March 2016 Thirty-one patients with AS (22 males, 9 females; mean age 39.6±12.3 years; range, 22 to 68 years) and 24 healthy controls (16 males, 8 females; mean age 40.8±8.9 years; range, 35 to 61 years) were enrolled. Patients’ clinical and demographic characteristics were recorded. Using OCT, we performed retinal nerve fiber layer (RNFL) thickness, ganglion cell complex, and ChT measurements in AS patients before and six months after the initiation of infliximab therapy, and in healthy controls. Results At baseline, patients with AS had higher ChT (mean±standard deviation: 347.5±114.4 μm) compared to healthy controls (322.1±62.8 μm), although this did not reach statistical significance level (p=0.283). At six months after the first measurement, the mean ChT was significantly decreased (under infliximab therapy: 326.5±99.7 μm vs. before: 347.5±114.4 μm, p=0.018) in AS group, while no significant change was observed in the control group (p=0.102). RNFL thickness in the AS group was significantly decreased after six months of treatment with infliximab (p=0.008). Conclusion By evaluating the posterior eye segment of patients with AS using OCT, this study has demonstrated that active AS patients had higher ChT. The significant reduction in this ChT after infliximab therapy may be mediating the established effective suppressing action of infliximab on uveitis attacks.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Methodsmentioning

confidence: 99%